Bevenopran is primarily utilized in the field of medicine, particularly as an opioid antagonist. Its main application is in the treatment of opioid-induced constipation (OIC), a common side effect experienced by patients undergoing opioid therapy for chronic pain. By blocking the effects of opioids on the gastrointestinal tract, it helps to alleviate constipation without interfering with the pain-relieving properties of the opioids. This makes it a valuable option for patients who require long-term opioid management but struggle with the associated gastrointestinal issues. Additionally, it has been explored for potential use in managing other conditions related to opioid use, such as pruritus (itching) and urinary retention, though these applications are less common. Its targeted action on peripheral opioid receptors minimizes central nervous system side effects, enhancing its safety profile for patients.